Abbreviations: CVP 5 central venous pressure ; D o 2 5 systemic oxygen delivery ; EGDT 5 early goal-directed therapy ; GTH 5 global tissue hypoxia ; MAP 5 mean arterial pressure ; OER 5 systemic oxygen extraction ; PDH 5 pyruvate dehydrogenase ; Scv o 2 5 central venous oxygen saturation ; Sv o 2 5 mixed venous oxygen saturation ; o 2 5 oxygen consumption Q uantitative resuscitation in critically ill patients consists of structured cardiovascular interventions, such as intravascular volume expansion and vasoactive agent support, to achieve explicit predefi ned physiologic parameters or goals. The concept of quantitative resuscitation (also referred to as hemodynamic optimization or goal-directed therapy) as a treatment strategy to improve clinical outcome was fi rst reported in high-risk surgery patients. 1 A recent meta-analysis of randomized clinical trials that compared quantitative resuscitation with standard resuscitation in septic shock found that when therapy was initiated within 24 h of the onset of sep sis (six trials, 740 patients), resuscitation targeting specifi c physiologic end points improved mortality compared with standard resuscitation (39% vs 57%: OR, 0.50; 95% CI, 0.37-0.69). 2 In contrast, when therapy was initiated . 24 h after the onset of sepsis (three trials, 261 patients), resuscitation targeting specifi c physiologic end points did not improve mortality (64% vs 58% for standard resuscitation; OR, 1.16; 95% CI, 0.60-2.22). Although the data supporting the use of early quantitative resuscitation are robust, the optimal end points or goals of such therapy are controversial.
Q uantitative resuscitation in critically ill patients consists of structured cardiovascular interventions, such as intravascular volume expansion and vasoactive agent support, to achieve explicit predefi ned physiologic parameters or goals. The concept of quantitative resuscitation (also referred to as hemodynamic optimization or goal-directed therapy) as a treatment strategy to improve clinical outcome was fi rst reported in high-risk surgery patients. 1 A recent meta-analysis of randomized clinical trials that compared quantitative resuscitation with standard resuscitation in septic shock found that when therapy was initiated within 24 h of the onset of sep sis (six trials, 740 patients), resuscitation targeting specifi c physiologic end points improved mortality compared with standard resuscitation (39% vs 57%: OR, 0.50; 95% CI, 0.37-0.69). 2 In contrast, when therapy was initiated . 24 h after the onset of sepsis (three trials, 261 patients), resuscitation targeting specifi c physiologic end points did not improve mortality (64% vs 58% for standard resuscitation; OR, 1.16; 95% CI, 0.60-2.22). Although the data supporting the use of early quantitative resuscitation are robust, the optimal end points or goals of such therapy are controversial.
Currently, consensus guidelines recommend the use of central venous pressure (CVP), mean arterial pressure (MAP), urine output, and central venous oxygen saturation (Scv o 2 ) as resuscitation goals. 3 These recommendations are based largely on an ED-based clinical trial of quantitative resuscitation for septic shock, an approach termed "early goal-directed therapy," which was a single-center study published by Rivers et al 4 in 2001. In this trial, 263 patients with severe sepsis or septic shock were randomly assigned to therapy targeting an Scv o 2 of Ն 70% or to conventional therapy that did not target an Scv o 2 . In both groups, therapy targeted CVP, MAP, and urine output. Mortality was signifi cantly lower in the group that targeted an Scv o 2 of Ն 70% (31% vs 47%). Given that the only difference in the treatment protocols in this trial was the Scv o 2 target, the observed treatment effect appears to hinge on achieving this node of the algorithm. In contrast, earlier studies of critically ill patients that targeted mixed venous oxygen saturation (Sv o 2 ) of Ն 70% found no mortality benefi t. 5 Multiple studies have unfortunately documented important barriers to implementing and maintaining an ED-based quantitative resuscitation protocol for septic shock. 6 -8 Among these, the use of a central venous catheter and the need for specialty equipment such as a continuous central venous oxygen spectrophotometer, and the training required for it, were major barriers that limited generalizability. To begin to address these barriers, the Lactate Assessment in the Treatment of Early Sepsis (LACTATES) randomized multicenter noninferiority trial, the largest ED-based early sepsis resuscitation trial completed to date, was designed to compare the use of lactate clearance to Scv o 2 as the fi nal goal of early sepsis resuscitation. 9 In the study, enrolled patients were randomly assigned to one of two groups. Each group received structured quantitative resuscitation while in the ED. The Scv o 2 group (n 5 150) was resuscitated by sequentially providing the therapy needed to meet thresholds of CVP, followed by MAP, and then Scv o 2 of Ն 70%. The lactate clearance group (n 5 150) had similarly targeted thresholds in CVP and MAP, and then lactate clearance of Ն 10% or more. The study protocol was continued until all end points were achieved or for a maximum of 6 h. The published results of this study showed a 6% (95% CI, 2 3% to 14%) in-hospital mortality difference between the two study groups (17% in the lactate clearance group vs 23% in Scv o 2 group), confi rming the primary hypothesis of noninferiority.
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There are many evidence-based, data-driven, and logical arguments as to why lactate clearance monitoring is a superior therapeutic target to oxygen-derived variables such as Scv o 2 . First, the published experimental (randomized trial) evidence supporting the use of lactate clearance as a therapeutic target is more robust in terms of the number of multicenter studies. 9 , 10 Similar published experimental evidence supporting Sc vo 2 is derived only from single-center studies. 4 , 11 Furthermore, multicenter studies have failed to show the use of Sv o 2 as a resuscitation goal 5 ; however, unlike Scv o 2 or other oxygen-derived variables, the ability to clear lactate has consistently predicted better survival in published studies of sepsis resuscitation. 12 -15 Second, elevated lactate levels refl ect the total picture of energy metabolism in the acutely stressed patient with sepsis. Elevated blood lactate has long been known to refl ect anaerobic metabolism from tissue hypoxia in critically ill patients. 16 However, besides these anaerobic processes, aerobic (metabolic) mechanisms that affect the host's effi ciency of energy transfer contribute to lactate production in sepsis. Cytokine-mediated glucose uptake and catecholamine-stimulated Na-K pump overactivity can both result in increased pyruvate production that eventually will overwhelm the catalytic capacity of pyruvate dehydrogenase (PDH) and result in increased lactate because of either mass effect, sepsisinduced PDH dysfunction, or both. This mechanism may explain part of the lactate production observed from the lungs and WBC in response to the infl ammatory stress, rather than tissue hypoxia of sepsis. 17 Additionally, reduced lactate clearance may refl ect globally impaired metabolic function by the liver and kidney, both of which normally contribute to systemic lactate disposal through anaplerosis, a mechanism that carboxylates lactate and delivers it to the tricarboxylic acid cycle , independent of the action of PDH. 18 Recent studies have shown that early lactate clearance is associated with improvement in the biomarkers of infl ammation and organ dysfunction. 19 Thus, as opposed to Scv o 2 , which is a rudimentary indicator of only the balance between oxygen supply and demand, lactate clearance biologically refl ects more of the general homeostasis of the host and provides more meaningful data about the overall adequacy of the resuscitative processes.
Third, in some circumstances the use of Scv o 2 might erroneously lead a clinician to believe that the physiologic status of the patient has improved, when in fact it may not have improved. A recent multicenter study of 619 patients demonstrated that venous hyperoxia (Scv o 2 . 89%) is present in 36% of ED patients with septic shock and is associated with an increased risk of death, and, when adjusted for confounders, venous hyperoxia was actually associated with a higher risk of death than venous hypoxia (Scv o 2 , 70%). 20 In this situation, high Scv o 2 values represent either an inability to exchange oxygen because of impaired fl ow in the small vessels from dysfunctional vascular autoregulatory mechanisms and functional shunting of oxygen or the inability of cells to use the oxygen because of derangement of cellular respiration, so-called "cytopathic hypoxia." 21 Although the Rivers et al 4 protocol focuses on the correction of a low Scv o 2 level signifying impairment in macrovascular oxygen delivery, the algorithm treats venous hyperoxia the same as normoxia (Scv o 2 70%-90%). The finding that a high Scv o 2 is associated with increased mortality reminds us that tissue dysoxia may occur despite adequate global oxygen delivery and that this situation is not identifi ed by the pres ence of normal venous oxygen levels. However, impaired oxygen transfer at any point from the lungs to the nicotinamide adenine dinucleotide dehydrogenase enzyme will cause lactic acidosis, and clearing lactate levels almost always signifi es improvement in host oxygen use. 6 Finally, a recently reported secondary analysis of the LACTATES study 9 reported no signifi cant concordance in achieving lactate clearance and Scv o 2 goals when measured simultaneously in the same subject, suggesting that these tests may be measuring and/or providing data about physiologically distinct processes. If lactate clearance was , 10%, the mortality was 40%, but if the Scv o 2 was , 70%, the mortality was 11% (proportion difference 29%; 95% CI, 6%-50%). 22 In conclusion, early sepsis resuscitation remains a dynamic topic of research interest, with many important questions that have yet to be answered. As summarized in this report, the best available evidence suggests that if a clinician has to choose a single goal of early sepsis resuscitation, lactate clearance, as opposed to Scv o 2 , is the more appropriate goal to choose. 
I
n 2001, early goal-directed therapy (EGDT ) resulted in a 16% reduction in hospital mortality and, post hoc, a higher lactate clearance in severe sepsis and septic shock. 1 Multiple studies have confi rmed the validity and generalizability of EGDT, resulting in its adoption into the Surviving Sepsis Campaign Guidelines. 2 , 3 Nguyen et al 4 , 5 examined early lactate clearance and found a signifi cant retrospective association with infl ammation, apoptosis, coagulation, organ dysfunction, and mortality. Following this rationale, Jones et al 6 modifi ed the EGDT protocol in 2010 using a noninferiority study design and concluded that lactate clearance is equivalent to central venous oxygen saturation (Scv o 2 ) in the management of individual patients.
Before applying the fi ndings of Jones et al 6 Sepsis may consist of four hemodynamic phases where a decreased Scv o 2 /Sv o 2 always precedes the appearance of lactate, making them complementary and nonexclusive end points, ( Fig 1, Table 1 ). These hemodynamic phases are not always distinct and may overlap depending on the timing and quality of the resuscitation. By characterizing these phases in hemodynamic outcome studies, future trials can be conducted with the appropriate research design and interpreted with clarity, facilitating generalizability and external validation in clinical management. 15 
Lactate Kinetics Are Complex and Limit the Interpretation of Lactate Levels and Lactate Clearance in the Individual Patient
Lactate elevation may indicate stress-induced upregulation in epinephrine-stimulated sodium-potassium adenosine triphosphatase activity in skeletal muscle and inhibition of pyruvate metabolism rather than, or in addition to, the traditionally implicated cellular hypoxia. Other confounding infl uences may include exogenous lactate sources (Ringers lactate or packed RBC transfusions), lactate shuttles and transport, delayed washout from underperfused tissue, variable lactate clearance by a number of organs, and dilution (large-volume resuscitations) ( Fig 2 ) . These interactions are not in a steady state and depend on the pathophysiology, timing, and quality of the resuscitation in the individual case. 16 Normal lactate levels occur in up to 45% of cases of septic shock, and although there is signifi cant variability, the associated mortality can be up to 52%. 9 , 17 -19 In fact, many patients develop multisystem organ failure and die without ever having increased lactate levels. 9 Thus, lactate has limitations as a tool for risk stratifi cation and as a guide for resuscitation in individual patients. In the Jones et al 6 study, the lactate clearance goal was at least 10% at Ն 2 h or normality of both initial and subsequent lactates. Nguyen et al, 20 however , found an optimal lactate clearance cutoff of , 10% after 6 h of intervention to have a sensitivity of 44.7%, specifi city of 84.4%, and accuracy of only 67.6% for predicting in-hospital mortality. Additionally, lactate clearance was less predictive of outcome in septic shock, the predominant feature of the patients in the Jones et al 6 study. Because of the variable expression of lactate, its complicated kinetics, and the limited accuracy of early hemodynamic patterns, and therapeutic interventions between those of Jones et al 6 and the EGDT study. 1 Further, review the complexities of lactate kinetics and the weaknesses of a noninferiority study design. 7 Based on these facts, it is clear that lactate clearance and Scv o 2 are not equivalent, but complementary goals for the individual patient.
The Hemodynamic Phases of Severe Sepsis and Septic Shock
The early stages of sepsis are accompanied by circulatory insuffi ciency that results from hypovolemia, vasomotor dysfunction, myocardial depression, and increased metabolic demands. In the systemic oxygen delivery (D o 2 )-dependent (hypodynamic) phase, a decrease in D o 2 results in a decrease in Scv o 2 /mixed venous oxygen saturation (Sv o 2 ) and usually an increase in systemic oxygen extraction (OER) or 1 2 Scv o 2 /Sv o 2 ( Fig 1, 8 Table 1 ). When the limits of the OER (anaerobic threshold) are reached, lactate is produced, signifying the development of global tissue hypoxia (GTH). There is signifi cant individual variation in the anaerobic threshold leading to variable lactate production. 9 This gives rise to why some patients may require normal or elevated D o 2 in order to resolve GTH (decreased Scv o 2 /Sv o 2 and increased lactate) ( Fig 1,  Table 1 ). GTH is associated with increased morbidity and mortality if not adequately treated. 10 , 11 Because GTH can occur with normal vital signs, it has been termed "cryptic shock." 12 GTH or cardiovascular insuffi ciency is a signifi cant part of the natural history of sepsis and responsible for the sudden cardiopulmonary deterioration seen in 12% to 21% of patients. 13 , 14 EGDT is associated with a 50% reduction in this adverse event, an issue not addressed by Jones et al. 6 With adequate volume therapy and myocardial reserve, a hyperdynamic or compensated phase follows. During this compensated phase, D o 2 is in the normal or elevated range, systemic oxygen consumption ( o 2 ) is increased, and vascular resistance is generally decreased. In contrast to the hypodynamic phase (patients in the Rivers et al 1 study), Jones et al 6 enrolled patients in this phase with a lower systolic BP, normal central venous pressure (CVP), normal Scv o 2 , lower lactate levels, and triple the frequency of vasopressor dependence ( Fig 1 ; Tables 1, 2 ). These patients also had corresponding Simplifi ed Acute Physiology Score II scores and predicted mortality that was nearly 14% lower than that in patients receiving EGDT (34.8% vs 48.4%) and other studies. 2 Pathological D o 2 dependency is a result of a progressive impairment of OER, which is accompanied by a markedly increased Scv o 2 /Sv o 2 (venous hyperoxia) and a hyperdynamic circulation. When D o 2 is insuffi cient, o 2 decreases, and increased lactate levels 17 Lactate levels over time can increase (negative clearance), stay the same, or decrease (positive clearance) after intervention ( Fig 2 ) . Not only is the direction of clearance impor tant but also the magnitude of change. There are signifi cantly different clinical and outcome implications in patients whose lactate levels decrease from 10 to 9 mmol/L vs 4 to 3.6 mmol/L. Although both represent clearance of 10%, the implications for illness severity and prognostic signifi cance are much different.
What
Optimization of preload (CVP) and afterload (mean arterial pressure) were addressed by Jones et al 6 ; however, the remaining components of EGDT, including optimizing D o 2 (oxygen carrying capacity [supplemental oxygen and hemoglobin], cardiac output) and decreasing o 2 (mechanical ventilation and sedation) to prevent delayed cardiopulmonary complications, were not elicited or examined. 15 Over the past decade, numerous studies have validated the clinical utility of Scv o 2 in recognizing supply dependency, need for a transfusion, detection of myocardial dysfunction, response to oxygen and mechanical ventilation, early cardiopulmonary complications, and overall infl uence on mortality. To establish noninferiority, lactate clearance has to be appropriately examined in these scenarios in order to be generalizable to all hemodynamic phases of sepsis and these facets of care. 7 The discrepancy between Scv o 2 -triggered interventions in the Rivers et al 1 study vs the 30 interventions (10% of patients) guided by lactate clearance refl ects signifi cant differences in hemodynamic phases, patient populations, and frequency and timing of interventions ( Fig 2 ) . This undermines the conclusion of equivalency from a noninferiority research design. 7 Patients more likely to require inotropes (congestive heart failure or coronary artery disease) or patients with reduced lactate clearance (liver failure) were not described by Jones et al 6 ( Table 2 ). This lower number of interventions refl ects a lower illness sever ity compared with other studies, 2 the possibility of poor compliance to the protocol, or a study design that is not equivalent to EGDT. The threefold greater use of vasopressors by Jones et al 6 may have resulted in higher lactate levels (catecholamines), CVP (increased afterload and venous tone), and Scv o 2 (decreased OER). As a result, triggers for more fl uid administration, RBC transfusion, inotropes, and mechanical ventilation may have been obscured by catecholamines. In this vasodilatory phase of sepsis, one would expect a higher use of corticosteroids 3 ; however, they were only used in 37% and 35% of eligible patients in the lactate clearance and Scv o 2 groups, respectively.
Real-World Clinical Practice
Central venous catheterization is recommended for patients with septic shock, and this was indeed the practice in the Jones et al 6 study. However, this study often is misinterpreted to imply that lactate clearance precludes the need for central venous catheterization altogether. This could result in a delay in a safer route for administration of vasopressors and achievement of EGDT goals within 6 h. The Surviving Sepsis Campaign recommendations include intermittent or continuous Scv o 2 sampling. 3 It is a simple matter to add intermittent Scv o 2 to lactate measurements in the absence of continuous monitoring. Bundle compliance and socioeconomic costs improve significantly with continuous monitoring. 21 
Conclusions

Rebuttal From Dr Jones
I
n their counterpoint, Dr Rivers and colleagues 1 present the theoretical view that patients with septic shock present in very distinct "hemodynamic phases" and that Jones et al 2 enrolled patients in a different phase of septic shock than did Rivers et al. 3 According to their theory, decreased central venous oxygen saturation (Scv o 2 ) always precedes the appearance of lactate-a concept not observed in my clinical practice. Clinicians who routinely care for the critically ill encounter patients with elevated lactate and normal Scv o 2 . Furthermore, as shown in Table 1 , 2 -10 the hemodynamic patterns of the subjects enrolled by Rivers et al 3 are markedly different from any other reported populations of patients with septic shock treated with quantitative resuscitation. The study by Rivers et al 3 patients had much higher lactate, much lower Scv o 2 , and much higher mortality than described elsewhere. Possible explanations for this discrepancy may include that patients with septic shock in Detroit between 1997 and 2000 were markedly different than any other septic shock population reported in the world's literature and/or that systematic selection bias was a signifi cant problem in the their study. In such a scenario, their results have questionable external validity. Supporting either of these assertions is the fact that mortality in the control group of the Rivers et al 3 study was 20% higher than any septic shock mortality reported in the recent literature, leaving one to question exactly what care they received. 3 Little evidence supports the contention that Jones et al 2 enrolled patients in a different phase of septic shock www.chestpubs.org
Rebuttal From Dr Jones
I
n their counterpoint, Dr Rivers and colleagues 1 present the theoretical view that patients with septic shock present in very distinct "hemodynamic phases" and that Jones et al 2 enrolled patients in a different phase of septic shock than did Rivers et al. 3 According to their theory, decreased central venous oxygen saturation (Scv o 2 ) always precedes the appearance of lactate-a concept not observed in my clinical practice. Clinicians who routinely care for the critically ill encounter patients with elevated lactate and normal Scv o 2 . Furthermore, as shown in Table 1 , 2 -10 the hemodynamic patterns of the subjects enrolled by Rivers et al 3 are markedly different from any other reported populations of patients with septic shock treated with quantitative resuscitation. The study by Rivers et al 3 patients had much higher lactate, much lower Scv o 2 , and much higher mortality than described elsewhere. Possible explanations for this discrepancy may include that patients with septic shock in Detroit between 1997 and 2000 were markedly different than any other septic shock population reported in the world's literature and/or that systematic selection bias was a signifi cant problem in the their study. In such a scenario, their results have questionable external validity. Supporting either of these assertions is the fact that mortality in the control group of the Rivers et al 3 study was 20% higher than any septic shock mortality reported in the recent literature, leaving one to question exactly what care they received. 3 Little evidence supports the contention that Jones et al 2 enrolled patients in a different phase of septic shock than did Rivers et al, 3 because the population enrolled by Jones et al 2 used inclusion cri teria identical to the Rivers et al 3 study. Furthermore, the population in the Jones et al 3 study appears to be an accurate contemporaneous population from three US EDs; it has characteristics, including mortality rates, nearly identical to those described from other studies ( Table 1 ) . Rivers et al 3 have raised the issue of potential methodologic limitations. They state that one must consider "weaknesses of the non inferiority study design" in the Jones et al 2 study. However, our study did not show equivalence (not worse than and not better than) but rather noninferiority (not worse than and maybe better than). This study design is the only design that could test the hypothesis at hand and, furthermore, the methodologic quality of a noninferiority and superiority randomized controlled trial is the same if properly conducted. So it is unclear exactly what "weaknesses" in our study are being criticized. On the other hand, there appear to be real methodologic concerns in the Rivers et al 3 trial. They failed to follow recommendations by not reporting whether any patients were randomized but not analyzed or performing an intention-to-treat analysis that could easily change the statistically signifi cant results of the trial.
Finally, the counterpoint 1 states that 45% of patients with septic shock present with a normal lactate and suggest that because of this, lactate is an inconsistent guide of resuscitation. 1 In fact, . 65% of patients in contemporaneous studies present with an Scv o 2 . 70%, and using their argument, these data make Scv o 2 an even more inconsistent resuscitative guide, particularly given that there is no therapy for markedly elevated and pathologic Scv o 2 (ie, . 90%). 2 , 5 Because data from an experimental clinical trial are the only way to scientifi cally deduce the clinical efficacy of lactate clearance vs Scv o 2 and because data from a large multicenter clinical trial demonstrated that lactate clearance is not inferior to Scv o 2 as an end point of early sepsis resuscitation, as described herein, lactate clearance has principles that may make it the more appropriate end point to choose.
Alan E. Jones , MD Jackson, MS
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Rebuttal From Dr Rivers et al
An End Point Must Be Consistently Present to Be Generalized L evraut et al 1 stated, "It is common knowledge that many septic patients develop multiple organ failure and die despite normal blood lactate levels." Below the critical systemic oxygen delivery, central venous oxygen saturation (Scv o 2 ) decreases; however, lactate level elevation may not occur. More importantly, an Scv o 2 Ն 70% is not the only goal, as achievement of all early goal-directed therapy (EGDT) goals actually resulted in an Scv o 2 Ն 77.3%. According to Dr Jones, 2 a study by Gattinoni et al 3 did not show an outcome benefi t of reaching a mixed venous oxygen saturation of 70% up to 48 h after ICU admission. However, Chamberlain et al 4 found in a meta-analysis that patients resuscitated to this end point within a more reasonable 6 h were twice as likely to survive than those without it.
A Repeat Look at a Previously Quoted Study
Dr Jones 2 cites the study by Jansen et al 5 as supportive of lactate clearance, but not all patients in that study were septic. Furthermore, the reduction of lactate was no faster when the control group therapy was compared with the lactate-guided aggressive resuscitation group. In fact, these authors concluded that "this observation might actually argue against lactate level as a target of hemodynamic therapy. However, given that Scv o 2 monitoring was mandatory in the lactate group and control group, we cannot exclude the possibility that this had an impact on the observed outcome difference." 5 
Does Noninferiority Mean Equivalency? Be Careful What You Read
Noninferiority is a double negative that may confuse clinicians because of the complexity of study design. Noninferiority trials are contro versial and diffi cult to design, conduct, analyze, and interpret for trialists, clinicians, reviewers, and editors. 6 The low number of interventions observed by Jones et al 7 bias toward the conclusion of noninferiority. Thus, for appropriate interpretation, one must be aware of and apply the CONSORT (Consolidated Standards of Reporting Trials) recommendations on noninferiority and equivalence trials ( Table 1 ) . 6 -10 Responding to Perceived Barriers Barriers specifi ed by Dr Jones 2 are unacceptable as excuses for our failure to save lives. We do not avoid complex interventions for trauma, stroke, or myocardial infarction. Severe sepsis carries a mortality risk far in excess of these acknowledged emergencies. Surely, placement of central lines, as well as continuous or intermittent venous saturation measurement, should be well within the capabilities of competent emergency and critical care practitioners.
Conclusion
Today's clinical tools for assessing tissue perfusion, including Scv o 2 and lactate level, have benefi ts and limitations. Scv o 2 has a half-life of seconds, providing value as an early goal of resuscitation with interpretation potentially confounded by changes in systemic oxygen delivery, tissue extraction, and distribution of blood fl ow at both the macrocirculatory and microcirculatory levels. Serum lactate levels may remain normal before and throughout resuscitation or fl uctuate due to the complexities of lactate kinetics, causing one to question the clinical usefulness of lactate clearance. Moreover, a 10% drop in serum lactate level has different implications if the initial value is 12 mmol/L rather than 4 mmol/L . The concept of lactate clearance as the single goal of resuscitation is, therefore, fl awed and potentially dangerous. Today's prudent clinician will use both normalization of Scv o 2 and lactate levels to guide resuscitation rather than rely on one parameter alone.
Emanuel P. Rivers 4 found in a meta-analysis that patients resuscitated to this end point within a more reasonable 6 h were twice as likely to survive than those without it.
A Repeat Look at a Previously Quoted Study
Does Noninferiority Mean Equivalency? Be Careful What You Read
Conclusion
Emanuel P. Rivers • This technology is described as "technically diffi cult, unavailable in many tertiary care EDs, too complex, costly and takes time away from the patient."
• Scv o 2 is a "controversial" method of determining tissue oxygen delivery. Assumption, LC is equivalent to Scv o 2 :
• Increased lactate levels are ubiquitous in all patients with severe sepsis and septic shock.
Background of EGDT 8 :
• It has been replicated in various multiple studies comprising .
40 studies totaling . 10,000 patients.
• Reduces absolute mortality by 16%-18% in patients of equal illness severity.
• It is cost effective and decreases health-care resource consumption.
• The Scv o 2 technology is .
40 y old, requires seconds to calibrate, and is optional with intermittent sampling according to the SSC recommendations.
Rationale for a noninferiority design:
• To establish equipoise because comparing EGDT to a control group in a prospective randomized trial with informed consent would be unethical based on robust evidence of previous studies.
Methods Interventions Precise details of the interventions intended for each group, detailing whether the reference treatment in the noninferiority or equivalence trial is identical (or very similar) to that in any trial(s) that established effi cacy and how and when they were actually administered.
LC triggered interventions:
EGDT triggered interventions over 6 h:
• Supplemental oxygen Rivers et al 8 Other objectives:
• Disassemble a protocol "too complex" for the providers of care.
• Prove evidence that checking serial lactates is easier and a reliable equivalent to Scv o 2 .
• Find a simpler and more generalizable method to monitor the adequacy of D o 2 as a research imperative in the treatment of patients with severe infection.
Outcomes Clearly defi ned primary and secondary outcome measures, detailing whether the outcomes in the noninferiority or equivalence trial are identical (or very similar) to those in any trial(s) that established effi cacy of the reference treatment and, when applicable, any methods used to enhance the quality of measurements (eg, multiple observations, training of assessors).
• The primary end point was absolute in-hospital mortality rate.
• Secondary end points were ICU length of stay, hospital length of stay, ventilator-free days, and new onset multiple organ failure.
• Other end points assessed were the number of resuscitative goals achieved, administered treatments, and predefi ned protocol-related serious adverse events.
Sample size and statistical methods How sample size was determined, detailing whether it was calculated using a noninferiority or equivalence criterion and specifying the margin of equivalence with the rationale for its choice. When applicable, explanation of any interim analyses and stopping rules (and whether related to a noninferiority or equivalence hypothesis).
• Using a one-sided test of noninferiority, assuming a control group mortality rate of 25% and a 5
.05, a sample size of 150 per group gave 71% power to determine the intervention did not increase mortality by .
10%. Prevailing mortality in previous before and after intervention studies show a higher mortality. 8 • Baseline mortality of 47.6% Ϯ 5%
• After intervention mortality of 27.5% Ϯ
13%
• The required size of noninferiority trials is usually larger than that for superiority trials. 6 Blinding (masking) Whether participants, those administering the interventions, and those assessing the outcomes were blinded to group assignment. When relevant, how the success of blinding was evaluated.
• Blinding does not protect against bias nearly as well in a noninferiority trial as it does in a superiority trial.
Results Participant fl ow and recruitment Flow of participants through each stage (a diagram is strongly recommended). Specifi cally, for each group report the numbers of participants randomly assigned, receiving intended treatment, completing the trial protocol, and analyzed for the primary outcome. Describe protocol deviations from trial as planned, together with reasons. One should avoid features that might dilute true differences between EGDT and LC, thereby enhancing the risk of erroneously concluding noninferiority:
• Poor adherence to the protocol • Dropouts • Recruitment of patients unlikely to need or respond to interventions (low illness severity and mortality) treatment crossovers. Rivers et al 8 Numbers analyzed Number of participants (denominator) in each group included in each analysis and whether "intentionto-treat" and/or alternative analyses were conducted. State the results in absolute numbers when feasible (e.g., 10 of 20, not 50%).
Jones et al 7 reported 30 interventions in 300 patients randomized:
• 10% (n 5 29) got to the point in the protocol where one of the two treatments being evaluated were administered (Scv o 2 ; n 5 13) and (LC; n 5
16).
Outcomes and estimation For each primary and secondary outcome, a summary of results for each group and the estimated effect size and its precision (eg, 95% CI). For the outcome(s) for which noninferiority or equivalence is hypothesized, a fi gure showing confi dence intervals and margins of equivalence may be useful. Patients were treated in the ED from the time of randomization until all treatment goals were achieved or 6 h had elapsed:
6-h end points are provided in the Rivers et al 8 study.
• No 6-h hemodynamic end points are reported.
• Although hematocrit was a therapeutic end point, no data were reported in reaching this end point in either group.
• There was no method to assess whether an indicated therapeutic action was performed in response to a parameter below the intended goal.
Adverse events All important adverse events or side effects in each intervention group. Delayed hemodynamic deterioration was not reported.
Delayed hemodynamic deterioration is an important feature in up to 20% of patients which was reduced to 10% with EGDT.
Interpretation and generalizability Generalizability (external validity) of the trial fi ndings.
• LC cannot be used in patients with nonelevated lactate levels.
• LC is unproven in patients with more complex presentations who require multiple interventions.
Overall evidence General interpretation of the results in the context of current evidence. • This study is underpowered to provide enough evidence to use LC as a replacement of Scv o 2 .
Additional contributions Untested hypothesis Clinicians must be confi dent that the new treatment would have been shown to be effi cacious if a placebo-controlled trial had been performed.
• Is there an outcome difference between a LC from 10 to 9 vs 4 to 3.6, both 10% clearance but different outcomes?
• How many lactate levels were required per patient to complete therapy and the time duration?
• Is LC cost effective as shown in EGDT?
• What is the technology assessment comparing the clinical utility of a precalibrated Scv o 2 and hourly or even more frequent lactate levels?
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